Pharvaris is a clinical-stage company focused on bringing oral bradykinin-B2-receptor antagonists to patients. By targeting this clinically proven therapeutic target with novel small molecules, the Pharvaris team is advancing new alternatives to injected therapies for all sub-types of HAE and other bradykinin-mediated diseases. The company brings together executives with a breadth of expertise across pharmaceutical development and rare disorders, including HAE.
The company reunites the core team responsible for the discovery and approval of the HAE treatment icatibant. With novel small molecules, we have identified and are advancing potent, orally available compounds targeting this clinically proven therapeutic target.
Company Details
- Employees
- 126
- Founded
- -
- Address
- Grafenauweg 8, Zug,6300,switzerland
- in****@****ris.com
- Industry
- Pharmaceutical Manufacturing
- NAICS
-
Pharmaceutical and Medicine ManufacturingMedicinal and Botanical ManufacturingPharmaceutical Preparation ManufacturingIn-Vitro Diagnostic Substance ManufacturingBiological Product (except Diagnostic) Manufacturing
- Website
- https://pharvaris.com
- Keywords
- Medicinal Chemistry, Hereditary Angioedema, Drug Discovery, Drug Development, Biotechnology, Pharmaceuticals.
- HQ
- Zug
Pharvaris Questions
Pharvaris's website is https://pharvaris.com
Pharvaris's LinkedIn profile is https://www.linkedin.com/company/pharvaris
Pharvaris has
126 employees.
View email and phone details for 126
employees at Pharvaris.
Pharvaris's industry is
Pharmaceutical Manufacturing
Pharvaris's top competitors are
Bristol Myers Squibb,
Spyre Therapeutics,
Argenx,
Biocryst Pharmaceuticals, Inc.,
Intellia Therapeutics, Inc.,
Ionis Pharmaceuticals, Inc.,
Kalvista Pharmaceuticals, Inc.,
Biogen,
Takeda,
Solid Biosciences.
Pharvaris's support email address is info@pharvaris.com
Pharvaris's categories are Pharmaceutical Manufacturing
Pharvaris's founding year is 2015
